Yuji Inagaki

Yuji Inagaki

Auto-generated profile, based on publicly available information

Yuji Inagaki

Department of Clinical Research Center, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2002 in Diabetologia
Verified
Journal Article
Closed access
YKYoshiro Koda
Yoshiro Koda
MSMikiko Soejima
Mikiko Soejima
SYSho-Ichi Yamagishi
Sho-Ichi Yamagishi
SAS. Amano
S. Amano
TOT. Okamoto
T. Okamoto
HKHiroshi Kimura
Hiroshi Kimura

20 February 2020 in Respirology Case Reports
Verified
Journal Article
Open access
PDF file
YIYuji Inagaki
Yuji Inagaki
KTKazunobu Tachibana
Kazunobu Tachibana
YIYasushi Inoue
Yasushi Inoue
TKTakahiko Kasai
Takahiko Kasai
YIYoshikazu Inoue
Yoshikazu Inoue
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a type of hypersensitivity drug reaction. Here, we report the case of a 78‐year‐old man who presented with a rash, fever, dry cough, and swollen parotid glands who had been prescribed clopidogrel for one year. Computed tomography showed consolidation and interlobular septal thickening with enlarged mediastinal lymph nodes. As oxygen therapy was ineffective, the patient was intubated and bronchoalveolar lavage cellular analysis showed an increase in eosinophils. Clopidogrel was discontinued and the parotid biopsy revealed periductal lymphocytic infiltration. High doses of corticosteroids were administered, and his symptoms improved. However, his symptoms recurred when clopidogrel was restarted. Skin biopsy showed mild lymphocytic infiltration in the upper dermis with vasculitis, and Epstein–Barr virus (EBV) DNA was detected in his blood and lymph node tissue. On the basis of the pathology and disease manifestations, the patient was diagnosed with DRESS. Once clopidogrel treatment ceased, his symptoms never recurred.

7 June 2021 in Turkish Thoracic Journal
Verified
Journal Article
Closed access
TETakatoshi Enomoto
Takatoshi Enomoto
YMYoshinobu Matsuda
Yoshinobu Matsuda
YAYuichi Adachi
Yuichi Adachi
SKShunichi Kouno
Shunichi Kouno
YIYuji Inagaki
Yuji Inagaki
YIYoshikazu Inoue
Yoshikazu Inoue
Capnography,carbon dioxide,blood gas analysis,interstitial lung disease

10 June 2024 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
THTakaaki Hasegawa
Takaaki Hasegawa
TOToru Okuyama
Toru Okuyama
TUTakehiro Uemura
Takehiro Uemura
YMYoshinobu Matsuda
Yoshinobu Matsuda
HOHiroyuki Otani
Hiroyuki Otani
TATatsuo Akechi
Tatsuo Akechi

6 November 2023 in Heliyon
Verified
Journal Article
Open access
ATAkihiro Tamiya
Akihiro Tamiya
KKKensuke Kanaoka
Kensuke Kanaoka
YIYuji Inagaki
Yuji Inagaki
YTYoshihiko Taniguchi
Yoshihiko Taniguchi
KNKeiko Nakao
Keiko Nakao
SSShigeki Shimizu
Shigeki Shimizu
Next-generation sequencing (NGS) analysis is becoming indispensable for the treatment of advanced lung cancer. NGS analysis requires a large number of cancer cell-containing tissues; however, it is often difficult for small biopsies to obtain the required quantities. In microdissection, only the tumour parts of a tissue specimen are obtained, which thereby increases the tumour content and tumour cell count of the tissue specimen. In this study, we investigated the extent to which the detection rate of genetic mutations changes by increasing the tumour content using microdissection. This is a retrospective study. In the genetic panel test using the Oncomine Dx Target Test (ODxTT), participants were divided into two groups: before (group A; April 2021–March 2022) and after (group B; April 2022–December 2022) the introduction of microdissection. The submission criteria for ODxTT were tumour content and tumour cell count >30 % and >2000 in group A, and >40 % and >5000 in group B, respectively. We compared the rate of genetic mutations detected using ODxTT between the two groups. This study included 214 consecutive ODxTT cases between April 2021 and December 2022. In group A (n = 112), 65 cases were adenocarcinoma, 84 involved lung tissue, and 64 underwent bronchoscopic sampling, whereas in group B (n = 102), 55 cases were adenocarcinoma, 91 cases involved lung tissue, and 79 cases underwent bronchoscopic sampling. Furthermore, genetic mutations were detected in 39 of 112 cases (35 %) in group A and 59 of 102 cases (58 %) in group B, which was statistically higher in group B (P = 0.0006). Genetic mutations were detected in 45 of 55 adenocarcinoma cases in group B. The genetic mutations detected in epidermal growth factor rescepor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), and mesenchymal epithelial transition (MET) were higher in group B. Increasing the number of tumour cells and tumour content can enhance the detection rate of genetic mutations using ODxTT.

16 October 2020 in Medicine
Verified
Journal Article
Open access
YIYuji Inagaki
Yuji Inagaki
ATAkihiro Tamiya
Akihiro Tamiya
YMYoshinobu Matsuda
Yoshinobu Matsuda
KAKouji Azuma
Kouji Azuma
YAYuichi Adachi
Yuichi Adachi
SAShinji Atagi
Shinji Atagi
Introduction: The clinical efficacy of osimertinib for patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations is unclear. Few case reports exist on the successful treatment of such tumors with osimertinib. We report a case wherein osimertinib administration had no effect in a patient with EGFR exon 20 insertion-positive lung adenocarcinoma. Patient concerns: A 48-year-old never-smoking woman was referred to our hospital for chronic cough. Computed tomography (CT) and positron emission tomography-CT revealed a nodule in the right middle lobe, consolidation in the right upper lobe, multiple lymph node metastases, liver metastasis, and multiple bone metastases. Diagnosis: On the basis of further examination using transbronchial lung biopsy, the patient was diagnosed with cT1N3M1 stage IVB lung adenocarcinoma. An EGFR exon 20 insertion, without any additional mutations, was identified. Interventions: Daily oral administration of 80 mg osimertinib was initiated to treat the EGFR exon 20 insertion-positive lung adenocarcinoma. Outcomes: Although the disease appeared to be stable 2.5 months after the administration of osimertinib, the tumor started to grow 3 months after administration, and carcinoembryonic antigen levels became higher than those before treatment. Thus, osimertinib was discontinued, and treatment with carboplatin as well as pemetrexed and bevacizumab was started, which the patient responded to. Conclusion: EGFR exon 20 insertion mutations must be classified in more detail to assess the efficacy of EGFR tyrosine kinase inhibitors. Osimertinib doses that provide favorable therapeutic windows should be considered. Further clinical research is required to clarify the efficacy of osimertinib and other drugs for exon 20 insertion mutations.